Cellectar Biosciences (CLRB) Assets (2010 - 2026)
Cellectar Biosciences (CLRB) posted Assets of $15.0 million for Q4 2025, up 2.4% sequentially from $14.6 million in Q3 2025, and down 41.2% YoY from $25.5 million in Q4 2024.
Cellectar Biosciences (CLRB) Assets (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Assets for 16 years, with the latest figure at $15.0 million in Q4 2025.
- Quarterly Assets fell 41.2% year-over-year to $15.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.0 million (down 41.2% YoY) and the FY2025 annual result came in at $15.0 million, down 41.2% from the prior year.
- Assets improved to $15.0 million in Q4 2025 per CLRB's latest filing, from $14.6 million in the prior quarter.
- Over five years, Assets peaked at $55.1 million in Q1 2021 and troughed at $6.5 million in Q2 2023.
- A 5-year average of $26.5 million and a median of $23.5 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2021 and 2023: Assets soared 533.69% in 2021, then tumbled 74.86% in 2023.
- Over 5 years, Assets stood at $37.2 million in 2021, then slumped by 41.97% to $21.6 million in 2022, then plunged by 44.07% to $12.1 million in 2023, then jumped by 110.96% to $25.5 million in 2024, then slumped by 41.2% to $15.0 million in 2025.
- According to Business Quant data, Assets over the past three periods registered $15.0 million, $14.6 million, and $13.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | 36.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.64 Mn |
| Dec 31, 2025 | 14.98 Mn |
| Sep 30, 2025 | 14.63 Mn |
| Jun 30, 2025 | 13.70 Mn |
| Mar 31, 2025 | 16.04 Mn |
| Dec 31, 2024 | 25.47 Mn |
| Sep 30, 2024 | 37.29 Mn |
| Jun 30, 2024 | 29.38 Mn |
| Mar 31, 2024 | 42.91 Mn |
| Dec 31, 2023 | 12.08 Mn |
| Sep 30, 2023 | 21.55 Mn |
| Jun 30, 2023 | 6.51 Mn |
| Mar 31, 2023 | 14.84 Mn |
| Dec 31, 2022 | 21.59 Mn |
| Sep 30, 2022 | 19.32 Mn |
| Jun 30, 2022 | 25.89 Mn |
| Mar 31, 2022 | 31.99 Mn |
| Dec 31, 2021 | 37.20 Mn |
| Sep 30, 2021 | 41.95 Mn |
| Jun 30, 2021 | 47.74 Mn |